Selected References:

• Chu S, et al. 2015. Periconceptional and Gestational Exposure to Antibiotics and Childhood Asthma. PLoS One 10(10):e0140443
• Crider KS, et al. 2009. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 163(11):978-985.
• Czeizel AE, et al. 1999. A population-based case-control teratological study of three parenteral penicillins G. Congenital Anomalies 39:117-126.
• Dencker BB, et al. 2002. Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196-201.
• Gallager, JS. 1988. Anaphylaxis in pregnancy. Obstet Gynecol 71:491-493.
• Greene H, et al. 1946. Excretion of penicillin in human milk following parturition. Am J Obstet Gynecol 51:732-733.
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group: 299-313, 435.
• Jepsen P, et al. 2003. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 55(2):216-221.
• Kosim H. 1959. Intrauterine fetal death as a result of anaphylactic reaction to penicillin in a pregnant woman. Dapim Refuiim 18:136-137.
• Meeraus WH, et al. 2015. Association between antibiotic prescribing in pregnancy and cerebral palsy or epilepsy in children born at term: a cohort study using the health improvement network. PLoS One 10(3): e0122034.
• Nahum GG, et al. 2006. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107(5):1120-38.
• Njotto LL, et al. 2023. Maternal and early-life exposure to antibiotics and the risk of autism and attention-deficit hyperactivity disorder in childhood: a Swedish population-based cohort study. Drug Saf. 46(5):467-478.
• Ortqvist AK, et al. 2014. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. BMJ. 349:g6979.
• Ravid R & Toaff R. 1972. On the possible teratogenicity of antibiotic drugs administered during pregnancy – a prospective study. Drugs and Fetal Development: 505-510.
• Simons & Schatz. 2012. Anaphylaxis during pregnancy. J Allergy Clin Immunol 130(3): 597-606.

Selected References:

• Agache I, et al. 2010. Risk factors and asthma phenotypes in children and adults with seasonal allergic rhinitis. Phys Sportsmed 38(4):81-86.
• Cao S, et al. 2020. Changes in children’s asthma prevalence over two decades in Lanzhou: effects of socioeconomic, parental and household factors. J Thorac Dis 12(10):6365-6378.
• Centers for Disease Control and Prevention. 2020. General Information about Mold. Available from URL: https://www.cdc.gov/mold-health/about/index.html
• Centers for Disease Control and Prevention. 2004. Investigation of acute idiopathic pulmonary hemorrhage among infants – Massachusetts, December 2002-June 2003. MMWR 53:817-820.
• Centers for Disease Control and Prevention. 2020. Natural Disasters and Severe Weather. Mold after a Disaster. Available from URL: https://www.cdc.gov/disasters/mold/.
• Centers for Disease Control and Prevention. 2000. Update: pulmonary hermorrhage/hemosiderosis among infants – Cleveland, Ohio, 1993-1996. MMWR 49:180-184.
• DiPaolo JA, et al. 1967. Teratogenic response by hamsters, rats and mice to aflatoxin B1. Nature 215:638-9.
• Etzel RA, et al. 1998. Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 152:757-762.
• Gallant MJ, et al. 2020. Prenatal and early-life exposure to indoor air-polluting factors and allergic sensitization at 2 years of age. Ann Allergy Asthma Immunol 124(3):283-287.
• Hayes AW, et al. 1974. Teratogenic effects of ochratoxin A in mice. Teratology 9:93-7.
• Korpinen E. 1974. Studies on Stachybotrys alternans: effect of low doses of stachybotrys toxins on pregnancy of mice. Acta Path Microbiol Scand 82:457-464.
• Lee E, et al. 2020. Prenatal mold exposure is associated with development of atopic dermatitis in infants through allergic inflammation. J Pediatr (Rio J) 96:125–31.
• Loth EA, et al. 2015. Experimental Paracoccidioiomycosis in pregnant rats. Rev Inst Med Trop San Paulo 57(6): 515-518.
• Magoha H, et al. 2014. Association between aflatoxin M1 exposure through breast milk and growth impairment in infants from Northern Tanzania. World Mycotoxin J 7(3): 277-284.
• Magoha H, et al. 2014. Fumonisin B1 contamination in breast milk and its exposure in infants under 6 months of age in Rombo, Northern Tanzania. Food Chem Toxicol 74:112-116.
• Martyny JW, et al. 2005. Aerosolized sodium hypochlorite inhibits viability and allergenicity of mold on building materials. J Allergy Clin Immunol 116:630-635.
• Reddy CS, et al. 1981. Teratogenicity of secalonic acid D in mice. J Toxicol Environ Health 7:445-55.
• Strina A, et al. 2014. Risk factors for no-atopic asthma/wheeze in children and adolescents: a systematic review. Emerg Themes Epidemiol 11:5.
• US Environmental Protection Agency (EPA). 2024. Mold and Health. Available at URL: https://www.epa.gov/mold/mold-and-health
• US Environmental Protection Agency (EPA). 2018. Mold and Your Home. Available at URL: https://www.epa.gov/mold/mold-and-your-home.

Selected References:

• Alhomoud MA, et al. The Potential Preventive Effect of Pregnancy and Breastfeeding on Multiple Sclerosis. Eur Neurol. 2021;84(2):71-84.
• Amato MP and Portaccio E. 2015. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 29(3): 207-20.
• Andersen JB, et al. Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis: A Nationwide Danish Cross-sectional Study. Neurol Clin Pract. 2021 Aug;11(4):280-290.
• Arafa A, et al. Does multiple sclerosis increase the risk of preeclampsia? A systematic review and meta-analysis. Hypertens Pregnancy. 2021 Aug;40(3):180-185.
• Ashtari F, et al. Investigating the interaction between fertility, pregnancy, and multiple sclerosis. J Educ Health Promot. 2021 Jun 30;10:220.
• Berenguer-Ruiz L, et al. 2019. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. J Neurol 266(10):2512-2517.
• Bove R. 2016. Women’s Issues in Multiple Sclerosis. Semin Neurol. 36(2):154-62.
• Bsteh G, et al. 2020. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Australia. Mult Scler. 26(1): 69-78.
• Carta A, et al. Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Mult Scler J Exp Transl Clin. 2021 May 28;7(2).
• Coyle PK. 2016. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. May;9(3):198-210.
• Cuello JP, et al. 2017. Multiple sclerosis and pregnancy: a single-centre prospective comparative study. Neurologia. 32(2):92-98.
• D’Amico E, et al. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Mult Scler. 2021 Dec;27(14):2284-2287.
• Eid K, et al. Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study. Neurology. 2021 Jun 8;96(23):e2789-e2800.
• Fragoso YD, et al. 2013. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis, Clin Neurol Neurosurg. Feb;115(2): 154-9.
• Houtchens MK, et al. 2018. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018;91:e1559–69.
• Hughes SE, et al. 2014. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 20(6) 739–746.
• Jokubaitis VG, et al; MS Base Study Group. 2016. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 80(1):89-100.
• Lamaita R, et al. Multiple Sclerosis in Pregnancy and its Role in Female Fertility: A Systematic Review. JBRA Assist Reprod. 2021 Jul 21;25(3):493-499.
• Langer-Gould A. 2019. Pregnancy and family planning in multiple sclerosis. Continuum 25(3):773-792.
• Lu E, et al. 2014. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler Feb;20(9):1260-1264.
• Mahlanza TD, et al. Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. Mult Scler. 2021 Jan;27(1):79-89.
• Massarotti C, et al. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. J Clin Med. 2021 Nov 19;10(22):5401.
• Moccia M, et al. 2023. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. Journal of Neurology, Neurosurgery & Psychiatry, 94:689-697.
• Neuteboom RF, et al. 2012. Pregnancy in multiple sclerosis: clinical and self-report scales. J Neurol. 259(2):311-7.
• Paidas PJ, et al. 2012. Pregnancy and multiple sclerosis (MS): A beneficial association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*). Am J Reprod Immunol 68(6):456-64.
• Pecori C, et al. 2014. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 14:114.
• Sadovnick D. et al. 2023. The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis. Multiple Sclerosis Journal, 29(3), 407-414.
• Safarinejad MR. 2008. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 20(12):1368-1375.
• Villaverde-Gonzalez R, et al. 2020. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. Mult Scler Relat Disord. 46:102518.
• Voskuhl R, Momtazee C. 2017. Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding. Neurotherapeutics. 14(4):974-984.
• Weber-Schoendorfer C and Schaefer C. 2009. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 15(9):1037-1042.
• Zanghi A, et al. 2020. Pregnancy and the postpartum period in women with relatpsing-remitting multiple sclerosis treated with old and new disease-modifying treatments: A real-world multicenter experience. Front Neurol 11:105.
• Ziemssen T, et al. 2001. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 24(13):979-990.

Selected References:

• Abdel-Aleem H, et al. 2003. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol; 108(1):25-8.
• Abdelshafy A, et al. 2019. Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. Eur J Contracept Reprod Health Care 12: 1-6.
• Ameri A, et al. 2024. Effect of misoprostol versus oxytocin on delivery outcomes after labour induction in pregnant women: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 292:75-88.
• Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol; 207:188-192.
• Bernard N, et al. 2013. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG; 120:568-575.
• Bord I, et al. 2014. Misoprostol treatment for early pregnancy failure does not impair future fertility. Gynecol Endocrinol; 30(4):316-9.
• Brasil R, et al. 2000. Misoprostol and congenital anomalies. Pharmacoepidemiol Drug Saf; 9(5):401-3.
• Brown SE, et al. 2001. Vaginal misoprostol enhances intrauterine insemination. Hum Reprod 2001; 16(1):96-101.
• Coelho KE, et al. 2000. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet; 95(4):297-301.
• da Silva Dal Pizzol T, et al. 2006. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol; 22(4):666-71.
• Dal Pizzol Tda S, et al. 2008. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica; 24(6):1447-53.
• Genest DR, et al. 1999. Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Clin Dysmorphol; 8(1):53-8.
• Gonzalez CH, et al. 1993. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet; 47(1):59-64.
• Gonzalez CH, et al. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet; 351(9116):1624-7.
• Holmes LB, et al. 2018. Malformations attributed to the process of vascular disruption. Birth Defects Res; 110(2):98-107.
• Kandahari N, et al. 2023. Fetal heart rate patterns and the incidence of adverse events after oral misoprostol administration for cervical ripening among low-risk pregnancies. J Matern Fetal Neonatal Med. 36(1):2199344.
• Kim C, et al. 2017. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev; 1(1):CD007223.
• Orioli IM, Castilla EE. 2000. Epidemiological assessment of misoprostol teratogenicity. BJOG; 107(4):519-23.
• Ozbasli E, et al. 2022. Labor induction with intravaginal misoprostol versus spontaneous labor: maternal and neonatal outcomes. Biomed Res Int. 2022:2826927.
• Pastuszak AL, et al. 1998. Use of misoprostol during pregnancy and Möbius’ syndrome in infants. N Engl J Med; 338(26):1881-5.
• Patel F, Cusack J. 2019. Möbius sequence with central hypoventilation in a neonate after failed elective medical termination of pregnancy. Arch Dis Child Fetal Neonatal Ed; 104(1):F49.
• Pfizer Laboratories Div Pfizer Inc. Last updated July 9, 2021. Cytotec drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12.
• Schuler L, et al. 1999. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective controlled study. Reprod Toxicol; 13:147-151.
• Shimizu T, et al. 1992. Prostaglandin E1, E2, and F2 alpha in human milk and plasma. Biol Neonate; 61:222–5.
• Song J. 2000. Use of misoprostol in obstetrics and gynecology. Obstet Gynecol Surv; 55(8):503-10.
• van Look PF, von Hertzen H. 1995. Misoprostol and birth defects. BMJ; 310(6972):128.
• Vargas FR, et al. 2000. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet; 95(4):302-6.
• Vauzelle C, et al. 2013. Birth defects after exposure to misoprostol in the first trimester of pregnancy: Prospective follow-up study. Reprod Toxicol; 36:98-103.
• Vendramini-Pittoli S, et al. 2013. Clinical findings in children with congenital anomalies and misoprostol intrauterine exposure: a study of 38 cases. J Pediatr Genet. 2013 Dec;2(4):173-80.
• Vogel D, et al. 2004. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol; 191:2168-73.
• Yip SK, et al. 2000. Misoprostol’s effect on uterine arterial blood flow and fetal heart rate in early pregnancy. Obstet Gynecol; 95(2):232-5.

Selected References:

• Carmichael SL, et.al. 2005. Maternal progestin intake and risk of hypospadias. Archives of Pediatrics & Adolescent Medicine, 159(10):957-962.
• Check JH, et al. 1986. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril, 45:575-577.
• Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics, 108(3):776-789.
• American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. 2021. rPrediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol, 138(2):e65-e90.
• Devall AJ, et al. 2021. Progestogens for preventing miscarriage: A network meta-analysis. Cochrane Database Sys Rev, 4(4):CD013792.
• Duds I, et al. 2006. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom (Kyoto), 46:194-198.
• Fawzy M, et al. 2008. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet, 278(1):33-38.
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 389, 391-392, 394, 443, 478, 497.
• Heinonen OP, et al. 1977. Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med, 296:67-60.
• Massai R, et al. 2005. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception, 72:352-357.
• Michaelis J, et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology, 27:57-64.
• Norman JE, et al. 2009. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet, 373(9680):2034-2040.
• Practice Committee of the American Society for Reproductive Medicine. 2008. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertility and Sterility, 89(4):789-792.
• Practice Committee of the American Society for Reproductive Medicine. 2012. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility, 98(5):1103-1111.
• RamaRao S, et al. 2013. Progesterone vaginal ring: Introducing a contraceptive to meet the needs of breastfeeding women. Contraception, 88(5):591-598.
• Roy M, et al. 2020. Progesterone vaginal ring as a new contraceptive option for lactating mothers: Evidence from a multicenter non-randomized comparative clinical trial in India. Contraception, 102(3):159-167.
• Silver RI, et al. 1999. In vitro fertilization is associated with an increased risk of hypospadias. J Urology, 161(6):1954-1957.